Hematology Overview - Concepedia

Principles

Definition

Hematology is the academic discipline and medical specialty concerned with the study of blood, blood-forming organs, and blood diseases. This field investigates the cellular and molecular components of blood, their functions, and the diagnosis, treatment, and prevention of disorders affecting the hematopoietic system.

Ontological type

Key Disease Categories

Diagnostic Techniques

Therapeutic Approaches

Key developments

Key Figures

Physiology and Experimental Hematopoiesis era

E. Donnall Thomas [1] is highlighted for work linked with Harvard University [3] and the Massachusetts Institute of Technology [4] during the Physiology and Experimental Hematopoiesis era. His key contributions in this era center on early bone-marrow transplantation and the clinical recognition of graft-versus-host disease, as exemplified by the paper Clinical Manifestations of Graft-Versus-Host Disease in Human Recipients of Marrow from HL-A-Matched Sibling Donors [7], which underscored alloimmune complications and the potential for marrow reconstitution. Hans Wigzell [2] is associated with Karolinska Institutet [5] and the University of Zurich [6] during this era. His key contributions include immunophenotyping advances such as identifying surface markers on human T and B lymphocytes in the paper Surface Markers on Human T and B Lymphocytes [8], which opened new frontiers in understanding lymphocyte subsets and aided leukocyte separation methods central to hematology's era.

Transplant Immunology and Molecular Stratification era

Ronald Levy [1], associated with Harvard University [3] and the University of California, San Francisco [4], was a pivotal figure in hematology during the Transplant Immunology and Molecular Stratification era. His key contribution, the paper Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling [5], introduced molecularly defined subtypes that enabled earlier prognostication and more precise risk-based transplant and therapy decisions in this era. Patrick O. Brown [2], likewise connected with Harvard University [3] and the University of California, San Francisco [4], contributed to this era by applying gene expression insights to delineate lymphoma subtypes and drive molecular stratification. As a co-author on the same study [5], Brown [2] helped advance the use of gene-expression profiling as a basis for prognosis and targeted therapeutic strategies within transplant immunology frameworks.

Integrated Transplant-Immunotherapy and Genomics era

Philippe Moreau [1], affiliated with Institute of Cancer Research [3] and Washington University in St. Louis [4], stands as a leading figure in the Integrated Transplant-Immunotherapy and Genomics era. His contributions in this era include the regimens Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma [7], Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma [8], and Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma [9], illustrating a shift toward immune-based combinations and the integration of transplantation with systemic therapy to improve response durability. Meletios Α. Dimopoulos [2], with Harvard University [5] and University of California, Los Angeles [6], is another pillar of this era, bridging transplant strategies with targeted immunotherapies in hematologic malignancies. His key contributions include Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Myeloma [10], Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma [7], and Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma [8], illustrating the era’s emphasis on genotype-guided therapy and transplant-augmented immunotherapy to expand durable disease control.